{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:24:27Z","timestamp":1791228267254,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI145542, R01AI158160 and R01AI163042"],"award-info":[{"award-number":["R01AI145542, R01AI158160 and R01AI163042"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-68501-5","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:53:31Z","timestamp":1769014411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An ultra-long-acting dimeric bictegravir prodrug defined by a short pharmacokinetic tail"],"prefix":"10.1038","volume":"17","author":[{"given":"Mohammad Ullah","family":"Nayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7123-3034","authenticated-orcid":false,"given":"Brady","family":"Sillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2792-0718","authenticated-orcid":false,"given":"Srijanee","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0740-1201","authenticated-orcid":false,"given":"Brandon W.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2653-6834","authenticated-orcid":false,"given":"Ashrafi","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Thai Hoang","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyash","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhoomika","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-2359","authenticated-orcid":false,"given":"Prasanta K.","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alekha K.","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5047-0962","authenticated-orcid":false,"given":"Samuel M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-1292","authenticated-orcid":false,"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-0370","authenticated-orcid":false,"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1484-9331","authenticated-orcid":false,"given":"Benson","family":"Edagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"68501_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3389\/fphar.2017.00831","volume":"8","author":"SA Iacob","year":"2017","unstructured":"Iacob, S. A., Iacob, D. G. & Jugulete, G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Front. Pharmacol. 8, 831 (2017).","journal-title":"Front. Pharmacol."},{"key":"68501_CR2","doi-asserted-by":"crossref","unstructured":"Foka, F. E. T. & Mufhandu, H. T. Current ARTs, virologic failure, and implications for AIDS management: a systematic review. Viruses 15, 1732 (2023).","DOI":"10.3390\/v15081732"},{"key":"68501_CR3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","volume":"17","author":"DA Cobb","year":"2020","unstructured":"Cobb, D. A. et al. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin. Drug Deliv. 17, 1227\u20131238 (2020).","journal-title":"Expert Opin. Drug Deliv."},{"key":"68501_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","volume":"36","author":"S Swindells","year":"2022","unstructured":"Swindells, S. et al. Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS 36, 185 (2022).","journal-title":"AIDS"},{"key":"68501_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin, C. et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N. Engl. J. Med. 382, 1124\u20131135 (2020).","journal-title":"N. Engl. J. Med."},{"key":"68501_CR6","doi-asserted-by":"crossref","unstructured":"Smith, G. H. et al. Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection: 5-year results from the LATTE-2 study. Open Forum Infect. Dis. 8, ofab439 (2021).","DOI":"10.1093\/ofid\/ofab439"},{"key":"68501_CR7","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis, D. A. et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet 390, 1499\u20131510 (2017).","journal-title":"Lancet"},{"key":"68501_CR8","doi-asserted-by":"publisher","first-page":"S541","DOI":"10.1093\/cid\/ciac716","volume":"75","author":"SE Cooper","year":"2022","unstructured":"Cooper, S. E., Rosenblatt, J. & Gulick, R. M. Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries. Clin. Infect. Dis. 75, S541\u2013S548 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"68501_CR9","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","volume":"7","author":"RJ Landovitz","year":"2020","unstructured":"Landovitz, R. J. et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV 7, e472\u2013e481 (2020).","journal-title":"Lancet HIV"},{"key":"68501_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-021-01005-1","volume":"60","author":"D Hodge","year":"2021","unstructured":"Hodge, D. et al. Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin. Pharmacokinet. 60, 835\u2013853 (2021).","journal-title":"Clin. Pharmacokinet."},{"key":"68501_CR11","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s11904-022-00616-y","volume":"19","author":"UM Parikh","year":"2022","unstructured":"Parikh, U. M., Koss, C. A. & Mellors, J. W. Long-acting injectable cabotegravir for HIV prevention: What do we know and need to know about the risks and consequences of cabotegravir resistance?. Curr. HIV\/AIDS Rep. 19, 384\u2013393 (2022).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"68501_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12977-018-0440-3","volume":"15","author":"M Oliveira","year":"2018","unstructured":"Oliveira, M. et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology 15, 1\u201314 (2018).","journal-title":"Retrovirology"},{"key":"68501_CR13","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer, S. et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N. Engl. J. Med. 386, 1793\u20131803 (2022).","journal-title":"N. Engl. J. Med."},{"key":"68501_CR14","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","volume":"10","author":"SK Gupta","year":"2023","unstructured":"Gupta, S. K. et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Lancet HIV 10, e15\u2013e23 (2023).","journal-title":"Lancet HIV"},{"key":"68501_CR15","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.1128\/AAC.01474-16","volume":"60","author":"M Tsiang","year":"2016","unstructured":"Tsiang, M. et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob. Agents Chemother. 60, 7086\u20137097 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"68501_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36330-5","volume":"14","author":"IC Young","year":"2023","unstructured":"Young, I. C. et al. Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection. Nat. Commun. 14, 708 (2023).","journal-title":"Nat. Commun."},{"key":"68501_CR17","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41591-021-01479-3","volume":"27","author":"RP Matthews","year":"2021","unstructured":"Matthews, R. P. et al. Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial. Nat. Med. 27, 1712\u20131717 (2021).","journal-title":"Nat. Med."},{"key":"68501_CR18","doi-asserted-by":"publisher","first-page":"569373","DOI":"10.3389\/fphar.2020.569373","volume":"11","author":"M Gunawardana","year":"2020","unstructured":"Gunawardana, M. et al. Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis. Front. Pharmacol. 11, 569373 (2020).","journal-title":"Front. Pharmacol."},{"key":"68501_CR19","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1093\/jac\/dkac252","volume":"77","author":"I Massud","year":"2022","unstructured":"Massud, I. et al. Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model. J. Antimicrob. Chemother. 77, 2964\u20132971 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"68501_CR20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jconrel.2020.12.024","volume":"330","author":"D Karunakaran","year":"2021","unstructured":"Karunakaran, D. et al. Design and Testing of a Cabotegravir Implant for HIV Prevention. J. Control. Release 330, 658\u2013668 (2021).","journal-title":"J. Control. Release"},{"key":"68501_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/pharmaceutics11070315","volume":"11","author":"LM Johnson","year":"2019","unstructured":"Johnson, L. M. et al. Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV pre-exposure prophylaxis (PrEP). Pharmaceutics 11, 315 (2019).","journal-title":"Pharmaceutics"},{"key":"68501_CR22","doi-asserted-by":"publisher","unstructured":"Su, J. T. et al. A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques. Antimicrob. Agents Chemother. 64, https:\/\/doi.org\/10.1128\/aac.01893-19 (2020).","DOI":"10.1128\/aac.01893-19"},{"key":"68501_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2013.12.020","volume":"176","author":"RRS Thakur","year":"2014","unstructured":"Thakur, R. R. S., McMillan, H. L. & Jones, D. S. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants. J. Control. Release 176, 8\u201323 (2014).","journal-title":"J. Control. Release"},{"key":"68501_CR24","doi-asserted-by":"crossref","unstructured":"Romano J. W. et al. Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting. AIDS Res Hum Retroviruses. 37, 409\u2013420 (2021).","DOI":"10.1089\/aid.2021.0028"},{"key":"68501_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2217\/nnm-2017-0381","volume":"13","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. Nanomedicine 13, 871\u2013885 (2018).","journal-title":"Nanomedicine"},{"key":"68501_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30902-7","volume":"13","author":"S Deodhar","year":"2022","unstructured":"Deodhar, S. et al. Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation. Nat. Commun. 13, 3226 (2022).","journal-title":"Nat. Commun."},{"key":"68501_CR27","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","volume":"19","author":"TA Kulkarni","year":"2020","unstructured":"Kulkarni, T. A. et al. A year-long extended release nanoformulated cabotegravir prodrug. Nat. Mater. 19, 910\u2013920 (2020).","journal-title":"Nat. Mater."},{"key":"68501_CR28","first-page":"600","volume":"50","author":"PV Turner","year":"2011","unstructured":"Turner, P. V. et al. Administration of substances to laboratory animals: routes of administration and factors to consider. J. Am. Assoc. Lab Anim. Sci. 50, 600\u2013613 (2011).","journal-title":"J. Am. Assoc. Lab Anim. Sci."},{"key":"68501_CR29","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1002\/jps.24014","volume":"103","author":"N Darville","year":"2014","unstructured":"Darville, N. et al. Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats. J. Pharm. Sci. 103, 2072\u20132087 (2014).","journal-title":"J. Pharm. Sci."},{"key":"68501_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jconrel.2016.03.041","volume":"230","author":"N Darville","year":"2016","unstructured":"Darville, N. et al. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension. J. Control. Release 230, 95\u2013108 (2016).","journal-title":"J. Control. Release"},{"key":"68501_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23668-x","volume":"12","author":"N Gautam","year":"2021","unstructured":"Gautam, N. et al. Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir. Nat. Commun. 12, 3453 (2021).","journal-title":"Nat. Commun."},{"key":"68501_CR32","doi-asserted-by":"crossref","unstructured":"Darville, N. et al. Modeling the Time Course of the Tissue Responses to Intramuscular Long-acting Paliperidone Palmitate Nano-\/Microcrystals and Polystyrene Microspheres in the Rat. Toxicol Pathol. 44, 189\u2013210 (2016).","DOI":"10.1177\/0192623315618291"},{"key":"68501_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/QAI.0000000000001306","volume":"75","author":"JE Gallant","year":"2017","unstructured":"Gallant, J. E. et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J. Acquir. Immune Defic. Syndr. 75, 61\u201366 (2017).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"68501_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0168-3659(92)90085-6","volume":"19","author":"K Yamaguchi","year":"1992","unstructured":"Yamaguchi, K. & Anderson, J. M. Biocompatibility studies of naltrexone sustained release formulations. J. Control. release 19, 299\u2013314 (1992).","journal-title":"J. Control. release"},{"key":"68501_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev.matsci.31.1.81","volume":"31","author":"JM Anderson","year":"2001","unstructured":"Anderson, J. M. Biological responses to materials. Annu. Rev. Mater. Res. 31, 81\u2013110 (2001).","journal-title":"Annu. Rev. Mater. Res."},{"key":"68501_CR36","doi-asserted-by":"crossref","unstructured":"Anderson, J. M., Rodriguez, A. & Chang, D. T. Foreign body reaction to biomaterials. in Semin. Immunol. 20, 86\u2013100 (2008).","DOI":"10.1016\/j.smim.2007.11.004"},{"key":"68501_CR37","doi-asserted-by":"crossref","unstructured":"Grundy, S. M. Cholesterol: factors determining blood levels. in Encyclopedia of Human Nutrition 3rd edn (ed. Caballero, B.) 335\u2013340 (Academic Press, 2013).","DOI":"10.1016\/B978-0-12-375083-9.00051-9"},{"key":"68501_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05614-6","volume":"9","author":"D Senyilmaz-Tiebe","year":"2018","unstructured":"Senyilmaz-Tiebe, D. et al. Dietary stearic acid regulates mitochondria in vivo in humans. Nat. Commun. 9, 3129 (2018).","journal-title":"Nat. Commun."},{"key":"68501_CR39","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/COH.0000000000000168","volume":"10","author":"C Trezza","year":"2015","unstructured":"Trezza, C. et al. Formulation and pharmacology of long-acting cabotegravir. Curr. Opin. HIV AIDS 10, 239\u2013245 (2015).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"68501_CR40","doi-asserted-by":"publisher","first-page":"232595822110090","DOI":"10.1177\/23259582211009011","volume":"20","author":"KK Scarsi","year":"2021","unstructured":"Scarsi, K. K. & Swindells, S. The promise of improved adherence with long-acting antiretroviral therapy: What are the data?. J. Int Assoc. Provid AIDS Care 20, 23259582211009011 (2021).","journal-title":"J. Int Assoc. Provid AIDS Care"},{"key":"68501_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0420-7","volume":"15","author":"SJ Smith","year":"2018","unstructured":"Smith, S. J. et al. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology 15, 37 (2018).","journal-title":"Retrovirology"},{"key":"68501_CR42","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1080\/14656566.2023.2294918","volume":"24","author":"J Doan","year":"2023","unstructured":"Doan, J. et al. Expanding therapeutic options: lenacapavir + bictegravir as a potential treatment for HIV. Expert Opin. Pharmacother. 24, 1949\u20131956 (2023).","journal-title":"Expert Opin. Pharmacother."},{"key":"68501_CR43","unstructured":"Study to compare bictegravir\/lenacapavir versus current therapy in people with HIV-1 who are successfully treated with a complicated Regimen Clinicaltrials.gov: NIH National Library of Medicine. [cited 2023 Oct 9] (2022)."},{"key":"68501_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","volume":"151","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151, 53\u201365 (2018).","journal-title":"Biomaterials"},{"key":"68501_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-02885-x","volume":"9","author":"B Sillman","year":"2018","unstructured":"Sillman, B. et al. Creation of a long-acting nanoformulated dolutegravir. Nat. Commun. 9, 443 (2018).","journal-title":"Nat. Commun."},{"key":"68501_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25690-5","volume":"12","author":"DA Cobb","year":"2021","unstructured":"Cobb, D. A. et al. Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles. Nat. Commun. 12, 5458 (2021).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68501-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68501-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68501-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:02:12Z","timestamp":1771426932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68501-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68501"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68501-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5959131\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.E. and H.E.G. are cofounders of Exavir Therapeutics, Inc. and are inventors on patents that cover ULA BIC formulations. The authors declare that this work was produced solely by the authors and that no other individuals or entities influenced any aspects of the work, including, but not limited to, the study conception and design, data acquisition, analyses, and interpretation, and writing of the manuscript. The authors further declare that they have received no financial compensation from any other third parties for any aspects of the published work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1793"}}